CIPHE Joins ANTIVIRESPIR to Combat Emerging Respiratory Viruses
- CIPHE
- Jun 27, 2025
- 1 min read
CIPHE (Inserm – CNRS – AMU) is proud to actively participate in the VIROCRIB consortium, awarded under the 2024 PEPR Emerging Infectious Diseases – France 2030 initiative. This involvement reflects CIPHE’s commitment to addressing future health crises through cutting-edge research.
The ANTIVIRESPIR project, coordinated by Delphine Muriaux (IRIM/CEMIPAI – CNRS Montpellier), aims to screen, identify, and characterize new antivirals targeting emerging and re-emerging respiratory viruses. The project aligns with a national strategy to better anticipate and respond to future pandemics.
CIPHE’s contribution, led by Ana Zarubica, with support from Hervé Luche and Frederic Fiore, includes:
Investigating antiviral mechanisms in the context of respiratory viral infections
Utilizing advanced in vitro and in vivo models to understand pathophysiological and immune responses
Supporting the identification of effective therapeutic candidates
CIPHE collaborates with a network of scientific partners, including:
Sandrine Belouzard (CIIL, Lille)
Florence Mahuteau (Institut Curie, Orsay)
Jacques Lebreton (Nantes Université)
Manuel Rosa-Calatrava (RESPIVIR, CIRI, Lyon)
John De Vos (IRMB, Université de Montpellier)
The GAVO consortium (CNRS chemists) and ChemBioFrance national infrastructure
This ambitious program demonstrates CIPHE’s commitment to innovative solutions in public health and reinforces its role in advancing preclinical antiviral research.
